Ziv-aflibercept: A novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer

American Journal of Health-System Pharmacy

Volumn 70, Issue 21, 2013, Pages 1887-1896

  Chung, Clement ^a   Pherwani, Nisha ^b  

^a Lyndon B Johnson General Hospital   (United States)

^b Cardinal Pharmacy Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HUMAN; HYPERTENSION; IMMUNOGENICITY; LEUKOPENIA; METASTATIC COLORECTAL CANCER; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEADY STATE; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR VASCULARIZATION; COLORECTAL TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SURVIVAL RATE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901728473     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130143     Document Type: Review

References (56)

1. Parkin DM, Whelan SL, Ferlay J. Cancer incidence in five continents. Vol. VIII. Lyon, France: International Agency for Research on Cancer; 2002. IARC scientific publications no. 155.
2. American Cancer Society. Cancer facts and figures 2012. www.cancer.org/research/cancerfactsstatistics/cancer factsfigures2012/index (accessed 2012 Dec 25).
3. National Cancer Institute. SEER (surveillance, epidemiology and end results) statistics. http://seer.cancer.gov (accessed 2013 Jan 17).
4. Cidon EU. The challenge of metastatic colorectal cancer. Clin Med Insights Oncol. 2010; 4:55-60.
5. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum. 1997; 40:15-24.
6. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current opinions, current evidence. J Clin Oncol. 2005; 23:4553-60.
7. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000; 343:905-14.
8. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22:23-30.
9. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22:229-37.
10. Song X, Zhao Z, Barber B et al. Characterizing medical care by disease phase in metastatic colorectal cancer. J Oncol Pract. 2011; 7:25S-30S.
11. Ragnhammar P, Hafstrom L, Nygren P et al. A systemic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 2001; 40:282-308.
12. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26:2013-9.
13. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360:1408-17.
14. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004; 25:581-611.
15. Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999; 284:1994-8.
16. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008; 358:2039-49.
17. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987; 235:442-7.
18. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004; 9(suppl 1):2-10.
19. Chu QS. Aflibercept (AVE 0005): an alternative strategy for inhibiting tumor angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther. 2009; 9:263-71.
20. Shibuya M. Tyrosine kinase receptor Flt/VEGFR family: its characterization related to antiangiogenesis and cancer. Genes Cancer. 2010; 1:1119-23.
21. Holash J, Davis S, Papadopoulos N et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002; 99:11393-8.
22. Zaltrap (ziv-aflibercept) prescribing information. Bridgewater, NJ: sanofiaventis; 2012 Aug.
23. Avastin (bevacizumab) prescribing information. South San Francisco, CA: Genentech; 2011 Feb.
24. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307:58-62.
25. Rudge JS, Holash J, Hylton D et al. VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenesis blockade. Proc Natl Acad Sci USA. 2007; 104:18363-70.
26. Van Cutsem E, Khayat D, Verslype C et al. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5- fluorouracil and leucovorin in patients with advanced solid tumors. Eur J Cancer. 2013; 49:17-24.
27. Khayat D, Tejpar S, Spano JP et al. Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study. Eur J Cancer. 2013; 49:790-7.
28. Yamazaki K, Yoshino T, Yamaguchi K et al. Phase I dose escalation and pharmacokinetics study of intravenous aflibercept plus irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) in patients with metastatic colorectal cancer. J Clin Oncol. 2011; 29(suppl 4):538. Abstract.
29. Lockhart AC, Rothenberg ML, Dupont J et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010; 28:207-14.
30. Verslype C, Spano J, van Cutsem E et al. Validation of the selected dose of aflibercept (VEGF-Trap) plus irinotecan, 5- fluorouracil, and leucovorin (I-LV5FU2) in a phase I clinical trial of patients with advanced solid tumors: preliminary results. J Clin Oncol. 2008; 26(suppl 15):14540. Abstract.
31. Rixe O, Verslype C, Khayat D et al. A phase I dose-escalation (DE) and pharmacokinetics (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with advanced solid tumors (STs). J Clin Oncol. 2008; 26(suppl 15):3557. Abstract.
32. Fukasawa M, Kore M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res. 2004; 10:3327-32.
33. Dupont J, Rothenberg MI, Spriggs DR et al. Safety and pharmacokinetics of intravenous VEGF trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol. 2005; 23(suppl 16):3029. Abstract.
34. Isambert N, Freyer G, Zanetta S et al. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2012; 18:1743-50.
35. Yoshino T, Yamazaki K, Yamaguchi K. A phase I study of iv aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2013; 31:910-7.
36. Tang P, Cohen SJ, Kollmannsberger C et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res. 2012; 18:6023-31.
37. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen. J Clin Oncol. 2012; 30:3499-506.
38. National Comprehensive Cancer Network. Clinical practice guidelines in oncology, colon cancer. V.3.2013. www.nccn.org (accessed 2013 Mar 6).
39. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005; 23:3502-8.
40. Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev. 2012; 38:484-93.
41. Roodhart JM, Langenberg MH, Witteveen E. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008; 3:132-43.
42. Lankhorst S, Kappers MH, van Esch JH et al. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertension. 2013; 31:444-54.
43. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010; 102:596-604.
44. Eremina V, Quaggin SE. Biology of antiangiogenic therapy-induced thrombotic microangiopathy. Semin Nephrol. 2010; 30:582-90.
45. Drug topics. Ziv-aflibercept (Zaltrap). Red book online [Internet database]. Greenwood Village, CO: Thompson Micromedex. Updated periodically.
46. Swain S. The high cost of a cancer drug: an oncologist's view. www.nytimes.com/2012/10/20/opinion/the-highcost-of-a-cancer-drug-an-oncologistsview.html?-r=0 (accessed 2013 Mar 7).
47. Arnold D, Andre T, Bennouna J et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). J Clin Oncol. 2012; 30(suppl 18):CRA3503. Abstract.
48. Giantonio BJ, Catalano PJ, Neropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25:1539-44.
49. Masi G. A randomized phase III study evaluating the continuation of bevacizumab (BV) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received BV as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO). Presentation at 37th European Society for Medical Oncology Congress. Vienna, Austria; 2012 Sep 28-Oct 2.
50. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008; 26:5326-34.
51. Pericay C, Folprechr G, Saunders M et al. Phase 2 randomized, noncomparative, open-label study of aflibercept and modified FOLFOX6 in the first-line treatment of metastatic colorectal cancer. (AFFIRM). Ann Oncol. 2012; 23(suppl 4):IV16.
52. ClinicalTrials.gov. Aflibercerpt and FOLFOX6 treatment for previously untreated stage IV colorectal cancer. www.clinicaltrials.gov/show/NCT016522196 (accessed 2013 Mar 7).
53. Teng LS, Jin KT, He KF et al. Clinical applications of VEGF-Trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010; 73:449-56.
54. Novello S, Ramlay R, Gorbunova VA et al. Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic nonsmallcell lung cancer (NSCLC): final results of a multinational placebo controlled phase III trial (EFC10261-VITAL). In: Proceedings of 14th World Conference on Lung Cancer. Amsterdam, Netherlands; 2011 Jul 3-7. Abstract O43.06
55. Riess H, Manges R, Karasek P et al. Double-blind, placebo-controlled randomized phase III trial of aflibercept (A) plus gemcitabine (G) versus placebo (P) plus gemcitabine (G) in patients with metastatic pancreatic cancer: final results. In: Proceedings of 12th World Congress on Gastrointestinal Cancer. Barcelona, Spain; 2010 Jun 30-Jul 3. Abstract O-0006.
56. Tannock I, Fizazi K, Ivanov S et al. Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): results from the multinational phase III trial (VENICE). J Clin Oncol. 2013; 31(suppl 6):13. Abstract.